Interestingly, the most recent clinical trial reported the correlation of PBRM1 mutation with anti–PD-1 treatment response in CD8+ T no-infiltrated ccRCC (10). This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.